RECRUITING

NYSCF Scientific Discovery Biobank

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.

Official Title

NYSCF Scientific Discovery Biobank

Quick Facts

Study Start:2022-11-10
Study Completion:2045-11-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06203106

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Days
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 30 days or older.
  2. * Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control.
  3. * Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.
  4. * Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD/ADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and/or Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.
  5. * Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental/guardian consent.
  6. * Minors undergoing blood, and/or saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent.
  7. * Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent.
  1. * Wards of the state.
  2. * For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.
  3. * For prospective blood samples: history of coagulation disorder.
  4. * For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.

Contacts and Locations

Study Contact

Becca Wood, MS
CONTACT
212-927-1801
clinicalresearch@nyscf.org

Principal Investigator

Laura Andres-Martin, PhD
PRINCIPAL_INVESTIGATOR
New York Stem Cell Foundation Research Institute

Study Locations (Sites)

New York Stem Cell Foundation Research Institute
New York, New York, 10019
United States

Collaborators and Investigators

Sponsor: New York Stem Cell Foundation Research Institute

  • Laura Andres-Martin, PhD, PRINCIPAL_INVESTIGATOR, New York Stem Cell Foundation Research Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-10
Study Completion Date2045-11-10

Study Record Updates

Study Start Date2022-11-10
Study Completion Date2045-11-10

Terms related to this study

Keywords Provided by Researchers

  • ALS
  • Amyotrophic Lateral Sclerosis
  • Alzheimer Disease
  • Batten Disease
  • Corticobasal Degeneration
  • Dementia
  • Frontotemporal Dementia
  • Huntington Disease
  • Lewy Body Disease
  • Multiple Sclerosis
  • Multiple System Atrophy
  • Parkinson Disease
  • Parkinsonism
  • Progressive Supranuclear Palsy
  • INAD
  • Diabetes
  • Diabetes Type 1
  • Diabetes Type 2
  • Macular Degeneration
  • Women's Reproductive Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Uterine Cancer
  • Vaginal Cancer
  • Vulvar Cancer
  • PTSD
  • Post Traumatic Stress Disorder

Additional Relevant MeSH Terms

  • ALS
  • Amyotrophic Lateral Sclerosis
  • Alzheimer Disease
  • Alzheimer Disease, Early Onset
  • Alzheimer Disease, Late Onset
  • Batten Disease
  • Corticobasal Degeneration
  • Dementia
  • Frontotemporal Dementia
  • Huntington Disease
  • Lewy Body Disease
  • Multiple Sclerosis
  • Multiple System Atrophy
  • Parkinson Disease
  • Parkinson's Disease and Parkinsonism
  • Progressive Supranuclear Palsy
  • INAD
  • Diabetes
  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • Diabetes Mellitus, Type 1
  • Macular Degeneration
  • Ovarian Cancer
  • Cervical Cancer
  • Uterine Cancer
  • Vaginal Cancer
  • Vulvar Cancer
  • PTSD
  • Post Traumatic Stress Disorder